The TDT R&D Mission
To continuously search for improvements in
the diagnosis and treatment of gastrointestinal cancers and disease.
Since the Company's founding in 1994, TDT has been committed to
the complex process of research, clinical testing, product development
and the trials of safety and efficacy necessary to bring diagnostic
and therapeutic products to market. Not only is this a long and
arduous process, it also represents an investment of millions of
The focus of Research and Development at TDT seeks to take advantage
of its expertise in gastrointestinal biology, signal transduction
and molecular biology to achieve an understanding of the pathways
by which cells progress from the pre-cancerous to the cancerous
state. Through both industrial and academic collaborations, TDT
has applied state-of -the-art technologies in its search for new
markers for gastrointestinal cancers, to both diagnose and treat
patients more effectively.
To date, TDT has developed two diagnostic
products, one for staging colorectal cancer (lymph node test),
and one for the detection of recurrent disease (blood test). Work
is also underway to apply the technology to a broader clinical environment,
including therapeutics, in conjunction with pharmaceutical partners.
TDT's broader research portfolio encompasses multiple projects,
extending beyond colorectal cancer, to include pancreatic cancer,
breast cancer, gastric cancer, esophageal cancer, cancer vaccines,
anti-diarrheal therapy, and more.
An extensive and rapidly growing intellectual property portfolio
has been created, as a result of these research efforts. Currently,
TDT has worldwide, exclusive rights to 21 U.S. patents, 5 foreign
patents, and over 38 pending U.S. and foreign applications.